Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AstraZeneca tests new biologic in healthy volunteers – no cure expected

NCT ID NCT06103877

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and tolerability of an experimental drug called AZD1163 in 108 healthy volunteers. Participants received either the drug or a placebo by IV or injection, and researchers monitored side effects and how the drug moved through the body. Since this is a Phase 1 study in healthy people, there is no direct treatment benefit; the results will help decide whether to test the drug in patients with a specific disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD1163 (an experimental biologic drug given by IV or injection)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

108 people

The number who actually took part.

Started

Nov 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male and female participants with suitable veins for cannulation or repeated venipuncture * All females must have a negative pregnancy test * Females of childbearing potential must not be lactating and, if heterosexually active, agree to taking approved method/s of contraception * BMI between 18 and 32 kg/m\^2 and weigh at least 45 kg Exclusion Criteria: * Has received another new chemical entity * History of any disease or disorder which may put participant at risk in the study * Current or recurrent disease of clinical significance * Medical history of malignancies except for cervical carcinoma and non-melanoma skin cancer (NMSC) * Any clinically important illness, medical/procedure, or trauma * Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis result at screening * Any positive result on screening for serum hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HbcAb), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) * History of latent or active tuberculosis (TB) or exposure to endemic areas * Evidence of active TB or untreated/inadequately/inappropriately treated for latent TB * Positive testing for Covid-19 prior to dosing, case of Covid-19 within 4 weeks, or long-term Covid-19-related sequelae * Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing or presence of fever * Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG), and any clinically important abnormalities in the 12-lead ECG * Known or suspected history of alcohol or drug abuse or excessive intake of alcohol * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Glendale, California, 91206, United States

  • Research Site

    Brooklyn, Maryland, 21225, United States

  • Research Site

    Berlin, 14050, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.